Skip to main content Skip to navigation
Purified Mouse Anti-FEZ1
Product Details
Down Arrow Up Arrow

BD Transduction Laboratories™
Rat (QC Testing), Human, Mouse (Tested in Development)
Mouse IgG1
Human FEZ1 aa. 381-592
Western blot (Routinely Tested), Immunofluorescence (Tested During Development)
75 kDa
250 µg/ml
Aqueous buffered solution containing BSA, glycerol, and ≤0.09% sodium azide.

Preparation And Storage

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. Store undiluted at -20°C.

Product Notices

  1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
  2. Please refer to for technical protocols.
  3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
611710 Rev. 1
Antibody Details
Down Arrow Up Arrow

The development of cancer is a multi-step process involving DNA alterations, oncogene activation, and/or the inactivation/deletion of an anti-onocogene or tumor suppressor. Tumor suppressors are involved in many facets of cell biology,such as cell cycle regulation and development. FEZ1 (F37/Esophageal cancer related gene-coding leucine zipper motif) is a putative DNA-binding protein with homology to cAMP-responsive activating-transcription factor 5 (Atf-5). The structure of FEZ1 includes DNA-binding and leucine zipper domains at amino acids 301-369 , as well as a putative cAMP-dependent phosphorylation site at Ser-29. FEZ1 is ubiquitously expressed in normal tissues with the most abundant expression in testes and brain, but is absent in 31 different cancer cell lines and 16 primary tumors. In addition, the FEZ1 gene has missense mutations in two primary esophageal cancers and a nonsense mutation in a prostate cancer cell line. Several FEZ1-expressing tumors have internally truncated FEZ1 mRNA transcripts. Thus, FEZ1 inactivation in cancers may involve both allelic loss and point mutations and implicates FEZ1 in cAMP-dependent tumor suppression.

This antibody is routinely tested by western blot analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.

611710 Rev. 1
Format Details
Down Arrow Up Arrow
Tissue culture supernatant is purified by either protein A/G or affinity purification methods. Both methods yield antibody in solution that is free of most other soluble proteins, lipids, etc. This format provides pure antibody that is suitable for a number of downstream applications including: secondary labeling for flow cytometry or microscopy, ELISA, Western blot, etc.
611710 Rev.1
Citations & References
Down Arrow Up Arrow

Development References (2)

  1. Ishii H, Baffa R, Numata SI, et al. The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. Proc Natl Acad Sci U S A. 1999; 96(7):3928-3933. (Biology). View Reference
  2. MacGrogan D, Levy A, Bova GS, Isaacs WB, Bookstein R. Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics. 1996; 35(1):55-65. (Biology). View Reference
611710 Rev. 1

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.